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Introduction
The human Ras proteins -H-Ras, N-Ras, K-Ras (K-Ras4A, K-Ras4B) -are the most well-known members of the Ras family. They have been extensively studied for over 30 years partly because of their high frequency of activating mutations in human cancers (1) . Ras proteins function as GDP/GTP molecular switches that regulate diverse signaling pathways and cell functions (1) . Cycling between GDP-and GTP-bound states of Ras is controlled by two classes of regulatory molecules: guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) (2) . GEFs facilitate the intrinsic GDP/GTP exchange activity of Ras, whereas GAPs stimulate the relatively slow intrinsic GTP hydrolysis activity of Ras. GTP-bound Ras regulates a complex signaling network by binding to and activating diverse classes of effector molecules, such as Raf, phosphatidylinositol 3-kinase (PI3K), and
RalGEFs (3).
Ras emanates signals not only from the plasma membrane but also from organelles, including the Golgi complex, the endoplasmic reticulum (ER), mitochondria, and endosomes (4) . The biological significance for compartmentalized Ras signaling was initially described in T lymphocytes, in which the activation of Ras-MAPK signaling at different subcellular compartments could lead to either negative or positive selection of T lymphocytes (5) . The compartmentalized Ras signaling is also conserved in fission yeasts. Ras1p, a single Ras March 12, 2012 ; DOI: 10.1158/0008-5472. protein in Schizosaccharomyces pombe, regulates mating from the plasma membrane and cell morphology from the endomembranes (6) . Therefore, the biological functions elicited by Ras are closely related to its subcellular localizations.
Cellular Src (c-Src), a non-receptor protein tyrosine kinase, has been implicated in the regulation of a variety of cellular functions (7, 8) . To exert such diverse biological activities, c-Src interacts with and phosphorylates a wide range of cellular proteins (7) . Crystallographic analysis has revealed that the Src-homology (SH) 2 and SH3 domains of c-Src bind to its own tyrosine 527 and a short polyproline type II helix between the SH2 and kinase domain, leaving c-Src in a close, autoinhibited state (9) . Interactions of c-Src with other cellular proteins via its SH2 and/or SH3 domains could disrupt the intramolecular inhibitory interactions, resulting in c-Src autophosphorylation on tyrosine 416 in the activation loop within the kinase domain for its full activation (7) . Although c-Src is frequently found to be hyper-activated in human cancers, its genetic mutations are rarely observed (10) .
It has been known for years that oncogenic Src (v-Src) can lead to Ras activation through different modes. For example, v-Src can phosphorylate the adaptor protein Shc, which then recruits Grb2/Sos complexes for Ras activation (11) . Additionally, Ras has been demonstrated to be essential for v-Src-stimulated cell transformation (12) . However, it is unclear whether oncogenic Ras could lead to the activation of c-Src. In particular, as activation of Ras and c-Src are frequently found in human cancers, clarification of their causal Liu (National Cheng Kung University, Taiwan) and described previously (13) . Re-introduction of c-Src into SYF cell line (SYF/c-Src) was established by retroviral infection. The SYF/H-Ras V12 and SYF/c-Src and H-Ras V12 cell lines were established by co-transfection with pBabe-puro and pcDNA3-HA-H-Ras V12 plasmids. Cells were selected and maintained in DMEM containing 10% fetal bovine serum (HyClone) and 1 μg/ml puromycin. Transient transfection was carried out by Lipofectamine (Invitrogen) or FuGene HD (Roche).
shRNAs
The lentiviral expression system for shRNA was provided by the National RNAi Core Facility, Academia Sinica, Taiwan. The production and infection of lentiviruses and the targeted sequences of shRNAs are described in the Supplementary Materials and Methods.
Immunoprecipitation, Immunoblotting, and Src kinase assay
Immunoprecipitation, immunoblotting, and Src kinase assay were performed as described in the Supplementary Materials and Methods.
Biological assays
Biological assays including cell proliferation assay, cell survival assay, soft agar-colony formation assay, cell invasion assay, tumorigenicity assay, and metastasis assay are 
Confocal Microscopy
Cells were fixed, stained, and scanned by a Zeiss LSM 510 confocal microscope as described in the Supplementary Materials and Methods.
Statistical Analysis
The quantitative results are shown as the means ± SD. Statistical significance of two-way difference was assessed using the Student's t-test. 
Results

Oncogenic Ras induces c-Src activation
The possibility for oncogenic Ras to activate c-Src was first examined in human cancer cell lines that harbor oncogenic mutations in ras genes (14) . Depletion of oncogenic Ras Ras might be specific to oncogenic forms of Ras, since depletion of endogenous Ras did not affect c-Src activation by platelet-derived growth factor (Fig. 1G ) or cell adhesion (Fig. 1H ). 
Oncogenic Ras activates c-Src mainly on the Golgi complex and ER
Ras is known to localize to different membrane compartments via post-translational modifications, such as farnesylation or palmitoylation, on its carboxyl terminus (4) Golgi complex and ER is important for it to activate c-Src. Similarly, we found that K-Ras V12/C185S , which cannot be farnesylated, failed to activate c-Src (Fig. 2B ). By contrast,
, which is known to predominantly associate with endomembranes (17), activated c-Src more potently than K-Ras V12 (Fig. 2B) . Therefore, our results suggest that association of oncogenic Ras with endomembranes, in particular the Golgi complex and ER, may be crucial for it to activate c-Src. It is known that myristoylation of Src at Gly2 is required for its association with cellular membranes (18) . We employed c-Src-GFP (with a GSGS-linker between c-Src and GFP) and its G2A mutant to examine whether membrane association is required for c-Src to be activated by oncogenic Ras. We found that c-Src-GFP was retained in an inactive state and mainly resided at the perinuclear region in resting cells ( Supplementary Fig. S1C ). Upon stimulation by epidermal growth factor, c-Src-GFP became activated and was recruited to the plasma membrane ( Supplementary Fig. S1C ), indicating that the activity and subcellular localization of c-Src-GFP can be regulated in response to extracellular stimuli. Unlike c-Src-GFP, c-Src G2A -GFP was diffusely distributed in the cytoplasm and was refractory to be activated by H-Ras V12 ( Supplementary Fig. S1D ). Together, our results suggest that membrane tethering of oncogenic Ras and c-Src on the Golgi complex and ER may be essential for oncogenic Ras to activate c-Src.
Activation of c-Src by oncogenic Ras is not through alterations in ROS production, autocrine, or cell adhesion
How does oncogenic Ras induce c-Src activation? First, we examined whether reactive oxygen species (ROS) play a role in this regard. Oncogenic Ras was reported to induce large amount of ROS (19) . Because ROS has been shown to stimulate the activity of Src (8, Fig. S3E ). RLIP76△GAP is a dominant-negative construct for both RalA and RalB (23) . We found that neither expression of 
RLIP76△GAP nor depletion of RalA and RalB affected the activation of c-Src by oncogenic Ras (Supplementary Figs. S3F, G and H) . Therefore, our results indicate that PI3K, Raf, RalGEF, and Ral are less likely to be involved in Ras-induced activation of c-Src.
P120RasGAP is a key mediator for oncogenic Ras to activate c-Src
To identify the molecule(s) essential for oncogenic Ras to activate c-Src, a collection of shRNAs that target Ras effectors, GEFs and GAPs, was applied to our study. Through an unbiased screening, we identified p120RasGAP (RasGAP) as an effector for oncogenic Ras to activate c-Src. We found that knockdown of p120RasGAP reduced Src pY416 in 79% (11/14) of examined cancer cell lines ( Fig. 3A ; Table 1 ). Knockdown of both K-Ras and p120RasGAP had more profound inhibition in c-Src activation than knockdown of either one in SW480 cells, (Fig. 3B) , supporting that oncogenic Ras, RasGAP, and c-Src are in the same signaling axis. The reduced c-Src activity by p120RasGAP knockdown was rescued by expression of GFP-fused p120RasGAP in H-Ras V12 -transformed NIH3T3 cells (Fig. 3C and D) .
Moreover, knockdown of p120RasGAP impaired the ability of H-Ras L61 to activate c-Src (Fig.   3E ). Conversely, overexpression of p120RasGAP, but not its R789Q mutant deficient in Ras binding (24) , potentiated the ability of H-Ras L61 to activate c-Src (Fig. 3F) , indicating that binding of p120RasGAP to oncogenic Ras is important for c-Src activation. Of note, the Q938H mutant lacking GAP activity (24) (Fig. 3F) , indicating that the GAP activity of p120RasGAP is not required for it to promote the activation of c-Src by oncogenic Ras.
Oncogenic Ras interacts with c-Src via p120RasGAP
H-Ras L61 , but not H-Ras L61/C186S , forms stable complexes with endogenous c-Src and p120RasGAP in intact cells (Fig. 4A) . The interaction between H-Ras L61 and c-Src was specific because c-Src was not co-precipitated with constitutively active Rho V14 or Rac V12
( Supplementary Fig. S4A ). As GTP-bound H-Ras does not directly bind to c-Src in vitro ( Supplementary Fig. S4B ), it is possible that p120RasGAP may mediate the interaction between oncogenic Ras and c-Src. Indeed, depletion of p120RasGAP by shRNAs markedly reduced the association of c-Src with Ras L61 (Fig. 4B ) and the Golgi-targeted Ras L61/C186S (Fig.   4C ). Overexpression of p120RasGAP, but not its R789Q mutant defective in Ras binding, promoted the interaction between Ras L61 and c-Src (Fig. 4D) . Moreover, we found that H-Ras L61 promoted the interaction between p120RasGAP and c-Src (Fig. 4E) . In HT-1080 cancer cells, suppression of oncogenic Ras by Ras N17 or specific shRNA inhibited the binding of p120RasGAP to c-Src (Figs. 4F and G) . Thus, our results support a role for oncogenic Ras to facilitate the interaction between p120RasGAP and c-Src.
In accordance with this notion, we found that in the absence of oncogenic Ras, endogenous p120RasGAP was distributed throughout the cytoplasm in a tubule-like pattering and did not co-localize with the Golgi marker KDELR-GFP (Fig. 4H) . By contrast, in the presence of H-Ras V12 , p120RasGAP became condensed and co-localized with KDELR-GFP at the perinuclear region (Fig. 4H) , where it was co-localized with active c-Src (Fig. 4I) . In vitro, p120RasGAP bound to both SH2 and SH3 domains of c-Src (Supplementary Fig. S4C ).
Deletion of the amino-terminal proline-rich region in p120RasGAP significantly reduced its interaction with the SH3 domain of Src (Supplementary Fig. S4D ). Together, our results support a model that recruitment of p120RasGAP to the Golgi complex by oncogenic Ras facilitates the interaction of p120RasGAP with c-Src, which may alleviate the intramolecular inhibitory conformation of c-Src, leading to c-Src activation.
P120RasGAP-medaited activation of c-Src is essential for oncogenic Ras to promote tumor invasion
To examine the functional significance of c-Src activation in the transforming potential of oncogenic Ras, H-Ras V12 was co-expressed with or without c-Src in SYF (src -/-yes -/-fyn -/-) cells (Fig. 5A) . We found that H-Ras V12 by itself did not promote proliferation of SYF cells (Fig.   5B ), but it was sufficient to support anchorage-independent growth of SYF cells in soft agar (Fig. 5D ) and allowed them to form tumors in mice (Fig. 5E) . However, H-Ras V12 by itself failed to stimulate invasive and metastatic capabilities of SYF cells (Figs. 5F, G, and H). H-Ras To examine the significance of p120RasGAP in oncogenic Ras-induced malignant transformation, p120RasGAP was depleted in human SW480 colon cancer cells that express oncogenic K-Ras. Depletion of p120RasGAP by shRNA significantly decreased c-Src activity (Fig. 6A) and impaired the invasiveness of the cells (Fig. 6E) , but had no effect on cell proliferation, survival, and anchorage-independent growth (Figs. 6B, C, and D). Expression of GFP-p120RasGAP restored the c-Src activity and invasiveness in p120RasGAP-depleted SW480 cells (Figs. 6A and E) . These results suggest that c-Src activation may be essential for oncogenic Ras to promote cell invasion, but not anchorage-independent cell growth. It is worth noting that knockdown of p120RasGAP did not decrease the invasiveness of LoVo cells (Fig. S5) , in which c-Src activity is independent of p120RasGAP ( Fig. S5A ; Table 1 Although p120RasGAP serves as a negative regulator for normal Ras, it has been implicated as an effector for oncogenic Ras (25) (26) (27) . For instance, p120RasGAP was demonstrated to be important for oncogenc Ras to induce cell transformation (25) . In particular, interruption of the interaction between oncogenic Ras and p120RasGAP was shown to suppress Ras-induced transformation (26) . However, the direct targets for p120RasGAP in Ras-induced transformation were unclear. In this study, we demonstrated that p120RasGAP functions as an effector for oncogenic Ras to activate c-Src. Our results indicated that the Ras-binding capability of p120RasGAP, but not its GAP activity, is required for oncogenic Ras to activate c-Src (Fig. 3F) . In addition, we showed that p120RasGAP is recruited to the Golgi complex upon the expression of oncogenic Ras (Fig. 4H) . We thus propose that recruitment of p120RasGAP to the Golgi complex by binding to oncogenic Ras may cause conformational changes in p120RasGAP, thereby exposing its binding sites to c-Src. Moreover, we found that the expression level of p120RasGAP is up-regulated by oncogenic Ras (Supplementary Fig. S6 ), which could further contribute to Ras-induced cell transformation. P120RasGAP has been shown to interact with p190RhoGAP (28) . In this study, we found that depletion of p190RhoGAP does not affect c-Src activation by oncogenic Ras (Fig. S7) , suggest that p190RhoGAP is not involved in c-Src activation in context with oncogenic Ras.
In this study, we showed that c-Src activation is crucial for oncogenic Ras to stimulate recently that active c-Src phosphorylates and activates dynamin 2 to induce marked Golgi fragmentation and vesicle transport from the Golgi to the plasma membrane during secretory processes (29) . In addition, Golgi-associated c-Src may promote cell migration and invasion through its effect on protein glycosylation (30) . As alterations in the glycans of membrane proteins could lead to changes in cell adhesion and migration (31, 32) , it is possible that the Golgi-associated c-Src may alter protein glycosylation in a way that is beneficial for tumor invasion.
We demonstrated in this study that expression of oncogenic Ras induces c-Src activation.
In addition, we found that there is a high correlation between oncogenic Ras and c-Src activation in human cancer cell lines that harbor oncogenic mutations in ras genes (Table 1 ).
In accordance with our findings, Shields et al. (33) recently reported that elevated Src activity is detected in more than 60% of patients with pancreatic ductal adenocarcinoma, which is characterized with a high incidence of oncogenic mutations in the K-ras gene. In this study, we found that knockdown of oncogenic Ras or p120RasGAP by shRNAs led to suppression in c-Src activity in 79% of examined cell lines harboring oncogenic Ras mutations. Given that Ras is the most common target for somatic gain-of-function mutations in human cancers, clarification of the role of c-Src in Ras-dependent malignancy is important for determining clinical implication and may be helpful for the development of therapeutic strategies. 
